Peptide Library

Human study PLS-00208

A Phase 2 Study on Effect of Thymosin Beta 4 on Wound Healing in Patients With Epidermolysis Bullosa

Other design · 30 participants enrolled

Version 1 · published November 8, 2026 · evidence through November 8, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

Reports of this study

Every publication, registration and abstract describing this one study. Participants are counted once.

  • A Phase 2 Study on Effect of Thymosin Beta 4 on Wound Healing in Patients With Epidermolysis Bullosaregistry entry · NCT00311766 (TERMINATED, results posted, planned enrollment 30)

Design and participants

Design
Other design
Population
Patients with epidermolysis bullosa (wound healing study); age and other eligibility details not stated in the record
Conditions
Epidermolysis Bullosa
Setting
not stated
Planned enrollment (registry)
30
Enrolled
30
Randomized
Not reported
Completed follow-up
Not reported
Funding
not stated
Authors’ conflicts
not stated

Intervention and comparator

What each group received. Related peptides, analogs and combinations are never treated as the compound itself.

  • Thymosin Beta 4 (intervention) · thymosin-beta-4 · Thymosin beta 4, as listed in the registry interventions; formulation not stated · Not reported assigned
  • Placebo (comparator) · Placebo, as listed in the registry interventions · placebo · Not reported assigned

What the authors reported

As stated in the sources. This is the authors’ account, not Peptide Library’s assessment.

Wound healing

unclear outcome · patient-important · Not stated in the record; only the study title indicates wound healing is the focus

  • No results reported.

Adverse events

None reported. That is not evidence of safety.

Monitoring: not stated

Peptide Library’s assessment

An automated assessment, made by AI separately from the authors’ conclusions and not reviewed by a person. How risk of bias is assessed.

Limitations

  • abstract only: Only the registry entry is available; no publication, abstract or results data are included in the record.
  • incomplete follow up: The registry status is TERMINATED, so the study ended early and planned follow-up may not have been completed.
  • small or imprecise: Actual enrollment was only 30 participants across the thymosin beta 4 and placebo groups, limiting precision.
  • other: Randomization and blinding methods are not stated in the record despite the placebo comparator, so the design cannot be confirmed as an RCT.
  • selective reporting: The registry indicates results exist, but no outcome or adverse event results are present in the record to appraise.

No risk-of-bias assessment has been published for this study’s results.

Claims this study informs

Where each value comes from

  • arms: NCT NCT00311766, registry (interventions field) · extracted by AI (automated, not verified by a person)
  • design: NCT NCT00311766, registry (study_type and phases fields) · extracted by AI (automated, not verified by a person)
  • limitations: NCT NCT00311766, registry (status and has_results fields) · extracted by AI (automated, not verified by a person)
  • outcomes: NCT NCT00311766, title (study title) · extracted by AI (automated, not verified by a person)
  • participants: NCT NCT00311766, registry (enrollment and enrollment_type fields) · extracted by AI (automated, not verified by a person)
  • population: NCT NCT00311766, registry (conditions field) · extracted by AI (automated, not verified by a person)

  • Version 1 · published November 8, 2026 · evidence through November 8, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

These assessments describe published research. Records marked automated were produced by AI under the published methodology and have not been reviewed by a person; they can contain errors. None of this is medical advice, not a statement about any product’s safety for human use, and not a regulatory approval. Peptide Library’s vendor and partner relationships play no part in them (editorial independence).